[Joseph Stiglitz and Arjun Jayadev] India’s drug ruling is patently wise decision
Apr 14, 2013
NEW YORK ― The Indian Supreme Court’s refusal to uphold the patent on Gleevec, the blockbuster cancer drug developed by the Swiss pharmaceutical giant Novartis, is good news for many of those in India suffering from cancer. If other developing countries follow India’s example, it will be good news elsewhere, too: more money could be devoted to other needs, whether fighting AIDS, providing education, or making investments that enable growth and poverty reduction.But the Indian decision also means